|5th April 2016
Healthcare is changing. Developments in treatments are taking place faster than ever, more stakeholders are involved in making decisions around treatments, and these stakeholders have different, sometimes conflicting needs. In this context, insight is key to effective marketing in meeting the challenge to deliver value to an ever-broadening range of stakeholders.
In this article, Head of Commercial Matt Bolton and Head of Insight Martine Leroy talk through how insight informs strategy at Blue Latitude Health.
At Blue Latitude Health, we regard insight as the deep understanding of the space where external and internal customers meet. In this context, we refer to external customers as those making decisions that impact the success of your product or service, be they patients, physicians, payers, nurses or others. Internal customers refer to those members of a healthcare company that must be engaged and motivated to deliver for external customers, from the brand team, to capability leads or compliance. Gathering insight in this sense allows us the opportunity to identify where external customers expect the business to operate and to deliver, and importantly where internal customers want and are able to operate. After all, insight is only useful if it can be acted upon.
|16th August 2019
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
|26th July 2019
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
|16th July 2019
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.